ArticleEuropean radiology2022
Added-value of dynamic contrast-enhanced MRI on prediction of tumor recurrence in locally advanced cervical cancer treated with chemoradiotherapy.
Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 14 citations in OpenAlex.
- Clinical translation of a DWI-radiomics nomogram integrating serum biomarkers for pretreatment staging of cervical cancer.BMC medical imaging · 2026Article
- Intravoxel incoherent motion diffusion-weighted imaging and dynamic contrast-enhanced MRI for predicting parametrial invasion in cervical cancer.Abdominal radiology (New York) · 2024Article
- Vaginal microbial profile of cervical cancer patients receiving chemoradiotherapy: the potential involvement of Lactobacillus iners in recurrence.Journal of translational medicine · 2024Article
- The Utility of Contrast-Enhanced Magnetic Resonance Imaging in Uterine Cervical Cancer: A Systematic Review.Life (Basel, Switzerland) · 2023Review
- Development of a combined model incorporating clinical characteristics and magnetic resonance imaging features to enhance the predictive value of a prognostic model for locally advanced cervical cancer.Frontiers in oncology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate whether the DCE-MRI derived parameters integrated into clinical and conventional imaging variables may improve the prediction of tumor recurrence for locally advanced cervical cancer (LACC) patients following concurrent chemoradiotherapy (CCRT).
methodsBetween March 2014 and November 2019, 79 consecutive LACC patients who underwent pelvic MRI examinations with DCE-MRI sequence before treatment were prospectively enrolled. The primary outcome was disease-free survival (DFS). DCE-MRI derived parameters, conventional imaging, and clinical factors were collected. Univariate and multivariate Cox hazard regression analyses were performed to evaluate these parameters in the prediction of DFS. The independent and prognostic interested variables were combined to build a prediction model compared with the clinical International Federation of Gynecological (FIGO) staging system.
resultsLymph node metastasis (LNM) and the mean value of v
conclusionsThe v KEY POINTS: Lower v
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.